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Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and
nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in
nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infec-
tion. The following immunogens were used: RNA replicon particles derived from an attenuated strain of
Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombi-
nant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV;
and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected
nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from
that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines
in primates and that protection of primates may require different mechanisms.
bola virus (EBOV) and Marburg virus (MBGV), which
make up the family Filoviridae, cause severe hemorrhagic
disease in humans and nonhuman primates, killing up to 90%
of those infected. EBOV was first recognized in the former
Zaire in 1976. Subsequently, outbreaks have been documented
in Sudan, Gabon, the former Zaire, Côte d’Ivoire, and Uganda
(1-3). In addition to the African outbreaks, the species Reston
Ebola virus, which may be less pathogenic for humans, was
isolated from cynomolgus monkeys imported from the Philip-
pines to the United States (4). Although outbreaks of EBOV
have been self-limiting, the lack of an effective vaccine or
therapy has raised public health concerns about these emerg-
ing pathogens.
In early attempts to develop a vaccine against EBOV,
guinea pigs or nonhuman primates were vaccinated with for-
malin-fixed or heat-inactivated virion preparations. Results
from these studies were inconsistent: Lupton et al. (5) partially
protected guinea pigs against EBOV, while Mikhailov et al. (6)
achieved complete protection of four of five hamadryad
baboons by vaccinating them with an inactivated EBOV vac-
cine. However, other studies suggested that inactivated EBOV
did not induce sufficient immunity to reliably protect
hamadryl baboons against a lethal challenge (7). Conventional
strategies of attenuating viruses for use as human vaccines
have not been pursued for EBOV because of concerns about
reversion to a wild-type form. However, the possibility of fol-
lowing this strategy by using newly developed infectious
clones of EBOV may now be feasible (8).
Recent efforts have focused on the use of recombinant
DNA techniques to stimulate cytotoxic T-lymphocyte
responses. Vaccinating guinea pigs with plasmids against
EBOV nucleoprotein (NP), soluble glycoprotein, or glycopro-
tein (GP) elicited humoral and cellular immune responses
against these gene products but only partially protected them
against lethal challenge (9). However, results of this study
were difficult to interpret because all the guinea pigs were
killed 10 days after EBOV challenge, which is within the
expected survival time for untreated animals (8-14 days) (10).
In 2000, Sullivan et al. (11) reported protection of cynomolgus
monkeys from EBOV infection by injecting them with naked-
DNA GP, followed by an adenovirus-expressing GP booster.
Results of this study document the feasibility of vaccination
against EBOV. However, these results require confirmation
and further evaluation, as a low dose (6 PFU) was used for the
challenge. Other studies reported a protective effect of EBOV
vaccination with a low infective challenge dose (ten 50%
lethal doses [LD50]) (7); however, all vaccinated animals in
these dosing studies died after receiving higher infective doses
(100 and 1,000 LD50), which may more accurately mimic nat-
ural or nosocomial exposures.
Our efforts to develop a vaccine against EBOV focused on
several potential vaccine candidates. First, we used Venezuelan
equine encephalitis virus (VEEV)  replicon particles (VRP)
expressing EBOV genes known to protect guinea pigs and
mice from EBOV disease (10); VRP expressing MBGV genes
also protected guinea pigs and cynomolgus monkeys against
MBGV (12). Second, we used a recombinant Vaccinia virus
(VACV) system expressing EBOV GP and demonstrated that
this vector protected guinea pigs from EBOV hemorrhagic
fever (13). A third strategy used encapsulated, gamma-irradi-
ated EBOV particles in liposomes containing lipid A (14); and
the fourth approach evaluated vaccination with a concentrated,
gamma-irradiated whole-virion preparation. None of these
approaches, which successfully protected rodents from lethal
infection, were protective for cynomolgus or rhesus macaques
challenged with EBOV. *U.S. Army Medical Research Institute of Infectious Diseases, Fort
Detrick, Maryland, USA
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Materials and Methods
Cynomolgus macaques (Macaca fascicularis) or rhesus
macaques (M. mulatta) weighing 4 to 6 kg were used. For vac-
cine studies with VEE replicons, EBOV GP or NP genes were
introduced into the VEEV RNA as described (10). Groups of
three cynomolgus macaques were vaccinated with VRP that
expressed EBOV GP, EBOV NP, a mixture of EBOV GP and
EBOV NP, or a control antigen (influenza hemagglutinin) that
has no effect on EBOV immunity. Animals were vaccinated by
subcutaneous injection of 107 focus-forming units of VRP in a
total of 0.5 mL at one site. Vaccinations were repeated 28 days
after the first injection and 28 days after the second.
In conducting research with animals, the investigators fol-
lowed the Guide for the Care and Use of Laboratory Animals
prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources,
National Research Council (1996). The animal facilities and
animal care and use program of the U.S. Army Medical
Research Institute of Infectious Diseases are accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International.
For vaccine studies using primates, we adapted the optimal
immunization regimens determined from the rodent studies. For
the vaccine based on recombinant VACV, the EBOV GP gene
was inserted into a VACV transfer vector plasmid, and recombi-
nant VACV expressing EBOV GP were isolated as reported
(13). Three cynomolgus macaques were injected subcutane-
ously with the EBOV GP-expressing VACV vector. Injections
were repeated at 28 and 53 days after the first injection. 
For vaccine studies with inactivated EBOV whole-virion
preparation, viral particles were concentrated from Vero cell
culture fluids by ultracentrifugation in a sucrose density gradi-
ent. Infectivity titer of the preparation was approximately 8.0
log10 PFU/mL. The preparation was inactivated by exposure to
60Co gamma rays (6 x 106 rads). The absence of residual infec-
tivity was proven by exhaustive testing for residual infectivity
in assays in Vero cells (15,16). Two cynomolgus monkeys and
two rhesus monkeys were injected subcutaneously with a 50-
µg dose of the gamma-irradiated virion preparation in RIBI
adjuvant (Corixa, Hamilton, MT). As a further check on com-
plete viral inactivation, blood samples taken from the monkeys
3 and 5 days after they received the vaccine were free of infec-
tious viremia. Injections were repeated at days 7 and 35 after
the initial injection. 
For vaccine studies using a liposome formulation, three
cynomolgus monkeys were vaccinated with gamma-irradiated
virus encapsulated in liposomes containing lipid A, as
described for previous studies in mice (14). Animals received
1.0 mL of the liposome preparation by intravenous injections
that were repeated at 28 and 55 days after the initial vaccina-
tion. Four macaques (two cynomolgus and two rhesus) served
as unvaccinated controls for the VACV, gamma-inactivated
virion, and liposome studies. 
Anti-EBOV neutralizing antibody titers were monitored by
measuring plaque reduction in a constant virus:serum dilution
format (15). All macaques received intramuscular injections in
the leg with 1,000 PFU of the Zaire subtype of EBOV, which
was isolated from a human patient in 1995 (16). Blood was
obtained from all monkeys under Telazol anesthesia (Fort
Dodge Laboratories, Fort Dodge, IA) at 2- or 3-day intervals
postinfection to determine infectious viremia, neutralizing
antibody titers, and standard hematologic and clinical pathol-
ogy parameters. All terminally ill monkeys were killed and
necropsied for pathologic examination. Virus infectivity
assays on plasma and tissue homogenates were done by form-
ing plaques on Vero cell monolayers as described (15,16).
Tissues were immersion fixed in 10% neutral-buffered for-
malin and processed for histopathologic and immunohis-
tochemical characteristics as described (17-19). Replicate
sections of spleen were stained with phosphotungstic acid
hematoxylin to demonstrate polymerized fibrin. Sections of
spleen from five EBOV-infected guinea pigs and five mice
from previous studies (20,21) were similarly stained for poly-
merized fibrin. Portions of selected tissues from 11 monkeys
were also immersion fixed in 4% formaldehyde and 1% glut-
araldehyde and processed for transmission electron micros-
copy according to conventional procedures (17-19).
Results
Serologic Response
Prechallenge EBOV neutralization titers were measured
for the 26 nonhuman primates used in this study (Table 1).
Although all vaccinated animals seroconverted by immuno-
globulin G enzyme-linked immunosorbent assay, neutralizing
antibody (PRNT50) titers were very low. Only one macaque
vaccinated with VRP-expressed EBOV GP had detectable
Table 1. Prechallenge neutralization titers of Ebola virus (EBOV)-vac-
cinated monkeys
Nonhuman 
primate species
No. of 
animals
Vector Antigen Neutralization 
titersa
Cynomolgus 3 Replicon GP 0, 0, 0
Cynomolgus 3 Replicon NP 0, 0, 0
Cynomolgus 3 Replicon GP + NP 0, 0, 10
Cynomolgus 3 Replicon Influenza HA 0, 0, 0
Cynomolgus 3 Vaccinia GP 10, 20, 20
Cynomolgus 3 Liposome Inactivated 
virion
20, 40, 80
Cynomolgus 2 Inactivated 
virion
10, 20
Rhesus 2 Inactivated 
virion
10,b 20
Cynomolgus 2 None 0, 0
Rhesus 2 None 0, 0
aImmunoglobulin G enzyme-linked immunosorbent assay, neutralizing antibody 
(PRNT50) All vaccinated monkeys seroconverted by enzyme-linked immunosorbent 
assay before challenge.
bAnimal survived challenge.
GP, glycoprotein; NP, nucleoprotein.Emerging Infectious Diseases  •  Vol. 8, 5, May 2002 505
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neutralizing antibody. The marginal PRNT did not preclude
challenge of the monkeys; however, in previous studies, simi-
lar results were obtained when cynomolgus macaques were
vaccinated with the VRP expressing MBGV genes, yet the
animals were protected from lethal disease (12).
Challenge of Vaccinated Monkeys with EBOV
All animals, including the four untreated macaques, were
challenged with 1,000 PFU of EBOV. Timing of challenge
varied because of differences in the optimal immunization reg-
imens determined by preliminary testing in rodents. VRP-vac-
cinated animals were challenged 49 days after the third
vaccine dose. At postchallenge day 3, all animals became ill;
two animals from each vaccination group (i.e., GP, NP, GP +
NP, influenza HA) died on day 6, and the remaining animals
died on day 7 (Table 2). VACV GP-inoculated macaques were
challenged 45 days after the third vaccine dose, EBOV lipo-
some-vaccinated animals 35 days after the third vaccine dose,
and macaques vaccinated with the gamma-irradiated whole-
virion preparation 43 days after the third vaccine dose. Again,
all animals except one rhesus macaque, which received the
gamma-irradiated virion preparation, became ill on the third
day after challenge. Two cynomolgus macaques vaccinated
with the gamma-irradiated virion preparation, one VACV-GP
animal, and one untreated cynomolgus macaque died on
postchallenge day 6 (Table 2). The two remaining VACV-GP
animals died at day 7 after challenge, as did two of the animals
vaccinated with the EBOV liposome preparation and the
remaining untreated cynomolgus macaque. The untreated
rhesus macaques died on days 8 and 9 postchallenge; one
rhesus vaccinated with the gamma-irradiated virion prepara-
tion died on day 9, and the other survived challenge. The
remaining animal vaccinated with the EBOV liposome prepa-
ration died 11 days after challenge. The rhesus macaque that
survived challenge did not become ill during the study and had
a PRNT50 values >320 at day 26 postchallenge and 80 at days
26, 61, 99, and 902 postchallenge.
Histopathologic Examination
Conventional histopathologic and electron microscopic
examination of lymphatic tissues, liver, and gastrointestinal
tract showed no differences in lesions between the vaccinated
animals and the unvaccinated EBOV-infected controls. Deple-
tion and necrosis or apoptosis were noted in all lymphoid ger-
minal centers in spleen, peripheral, and mesenteric lymph
nodes, as described in other studies (17-19). The spleen had
copious deposits of fibrin throughout the red pulp, as well as
abundant karyorrhectic cellular debris. By electron micros-
copy, widespread bystander lymphocyte apoptosis was a
prominent feature in all the lymphatic tissues examined. Fibrin
and fibrinocellular thrombi were also prominent in the submu-
cosa of the gastrointestinal tract and in hepatic sinusoids, again
consistent with well-documented findings (17,18). 
We also evaluated retrospectively EBOV-infected rodent
tissues in parallel. Although sites of infection and morphologic
changes between guinea pigs, mice, and nonhuman primates
had many similarities, the lack of fibrin thrombi in spleen and
visceral vasculature was particularly striking in the EBOV-
infected mice (Figure). Fibrin deposition was seen in guinea
pigs as reported (20), but fibrin deposits and thrombi were
considerably less prevalent compared with deposits in nonhu-
man primates (Figure). Lymphocyte apoptosis was also less
frequently observed by electron microscopy in rodent lym-
phatic tissues than in nonhuman primates. EBOV was demon-
strated in liver, spleen, kidney, lung, adrenal gland, and lymph
nodes of all necropsied monkeys by immunohistochemistry,
electron microscopy, or virus infectivity titration. 
Discussion
Our results indicate that rodent models of EBOV hemor-
rhagic fever do not consistently predict efficacy of candidate
vaccines in nonhuman primates, perhaps because the disease
course in rodents differs from that reported in human and non-
human primates (17-19,22,23). Mice do not have the hallmark
disseminated intravascular coagulation (DIC) found in end-
stage lesions of humans and nonhuman primates. Viremia and
widespread tissue dissemination are much more apparent in
nonhuman primates than in guinea pigs (20). In addition,
guinea pigs have less DIC than do nonhuman primates. Lym-
phocyte apoptosis was not reported to be a prominent feature
of EBOV infection in mice or guinea pigs (20,21) but was a
consistent feature of disease in humans (24) and nonhuman
primates (19). Clinical disease and related pathologic features
in nonhuman primates infected with EBOV appear to more
closely resemble those described in human EBOV hemor-
rhagic fever (22,23). Other studies have shown inconsistencies
between rodent and nonhuman primate models of human hem-
orrhagic disease in the protective efficacy of candidate vac-
cines. For example, guinea pigs were protected from Lassa
virus by VACV recombinants expressing the viral nucleopro-
Table 2. Challenge of vaccinated monkeys with Ebola virus (EBOV)
NHP Species Vector Antigen
Survival/
total
Viremic/
total
Day of 
deatha
Cynomolgus Replicon GP 0/3 3/3 6, 6, 7
Cynomolgus Replicon NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon GP + NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon Influenza HA 0/3 3/3 6, 6, 7
Cynomolgus Vaccinia GP 0/3 3/3 6, 7, 7
Cynomolgus Liposome Inactivated 
virion
0/3 3/3 7, 7, 11
Cynomolgus Inactivated 
virion
0/2 2/2 6, 6
Rhesus Inactivated 
virion
1/2 2/2 9
Cynomolgus None 0/2 2/2 6, 7
Rhesus None 0/2 2/2 8, 9
aNumber of days after challenge with 1,000 PFU of EBOV. 
NHP, nonhuman primate; GP, glycoprotein; NP, nucleoprotein.PERSPECTIVES
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tein (25,26); however, this vaccination strategy failed to pro-
tect rhesus macaques (27).
The effort to develop an EBOV vaccine began after the ini-
tial identification of EBOV in 1976, but 25 years later the goal
remains elusive. Attempts to develop killed-virus vaccines
against EBOV hemorrhagic fever have had inconsistent results
(5-7). Recent progress in genetic vaccination strategies has
demonstrated that immunity can be achieved against a low
dose of EBOV. While protection against any lethal challenge
dose of EBOV is a remarkable achievement, we have set the
bar somewhat higher than 6 PFU, since a laboratory exposure
through a needlestick and infected blood would likely entail a
dose of at least 1,000 PFU. Therefore, our priority is to empir-
ically develop a vaccine that protects against at least 1,000
PFU rather than to initiate an exhaustive investigation of pro-
tective immune mechanisms. We were encouraged by the
demonstrated success of the VEEV replicon vector expressing
MBGV glycoprotein in protecting cynomolgus macaques from
challenge with homologous MBGV (12). No MBGV-neutral-
izing activity was observed at >1:20 dilutions in prechallenge
sera of any of the MBGV GP VRP-vaccinated macaques (12),
yet these animals did not become viremic, showed no signs of
disease, and survived challenge. Historically, Filovirus-neu-
tralizing antibodies have been difficult to demonstrate in vitro
(15); while the presence of neutralizing antibodies is desirable,
it is neither sufficient nor necessary to clear viral infection
(16). Unfortunately, the VEEV replicon strategy that was suc-
cessfully employed for MBGV in cynomolgus macaques and
for EBOV in mice and guinea pigs (10) did not protect cyno-
molgus macaques from EBOV disease. These differences
observed between EBOV and MBGV may result from differ-
ences in the course of infection. Specifically, the mean day of
death for untreated cynomolgus monkeys experimentally
infected intramuscularly with 1,000 PFU of EBOV (Zaire sub-
type) is 6.3 (n=15; data not shown), while the mean day of
death for cynomolgus monkeys infected intramuscularly with
a comparable dose of MBGV (Musoke isolate) is 9.1 (n=8;
data not shown). Thus, macaques infected with MGBV have
nearly three more days to mount an effective immune response
against the challenge virus than macaques infected with
EBOV (Zaire). Clearly, other variables, including differences
observed between EBOV (Zaire) and MBGV with respect to
GP gene expression (28), tropism, and host cell responses,
may contribute to differences in disease pathogenesis and out-
come of infections.
The induction of humoral and cytotoxic T-lymphocyte
responses to EBOV NP and GP has been demonstrated in
guinea pigs, although the relative contributions of these
responses to immune protection are unclear (9). Moreover,
transfer of EBOV immune serum in rodent and nonhuman pri-
mate models provided inconsistent results. Passive transfer of
immune serum from VRP-vaccinated animals did not protect
guinea pigs or mice against lethal challenge (10); however,
transfer of hyperimmune equine immune globulin (which had
high EBOV neutralization titers) to guinea pigs protected them
against disease (16,29). Passive treatment of cynomolgus
monkeys with the equine immune globulin delayed death but
did not ultimately protect the monkeys against lethal EBOV
hemorrhagic fever (16,29). In contrast, hamadryl baboons
were protected against lethal EBOV challenge by passive
treatment with the equine immune globulin and the use of a
lower challenge dose (30). These results suggest that cell-
mediated effector mechanisms may play a more important role
in protection than do humoral responses. Nonetheless, the role
of humoral immunity is in fact supported by studies showing
consistent delay in death or protection of primates therapeuti-
cally treated with EBOV-neutralizing antibodies (16,29,30).
We conclude that, although rodent models are useful as
preliminary screens for candidate vaccines and therapeutic
treatments, nonhuman primates likely provide a more useful
and definitive model for EBOV hemorrhagic fever in humans.
Furthermore, differences in disease pathology between rodent
and nonhuman primate models of EBOV suggest that protec-
tion of primates may require different protective mechanisms.
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Figure. Sections of spleen from Ebola virus (EBOV)-infected animals.
Top left, BALB/c mouse, note absence of polymerized fibrin (phospho-
tungstic acid [PTA] hematoxylin, original magnification X400). Field rep-
resentative of five of five mice tested. Top right: guinea pig. Note
discreet foci of polymerized fibrin (arrows) (PTA hematoxylin, original
magnification X400). This field shows infrequent fibrin deposits; most
fields in five of five animals examined showed no evidence of polymer-
ized fibrin. Lower left: cynomolgus monkey. Note deposition of polymer-
ized fibrin in red pulp (PTA hematoxylin, original magnification X400).
Field representative of 25 of 25 monkeys. Lower right: cynomolgus
monkey. Electron micrograph showing abundant fibrin deposits in pulp
(original magnification X5,300). Field representative of 11 of 11 mon-
keys examined.Emerging Infectious Diseases  •  Vol. 8, 5, May 2002 507
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